{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:17:02Z","timestamp":1760782622075},"reference-count":26,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Administration of agonistic monoclonal antibodies or recombinant cytokines is a potential approach to enhance antitumor immunity in bone marrow (BM) transplant recipients, but is complicated by toxicity due to proinflammatory cytokine-mediated vital organ damage. We used a murine syngeneic bone marrow transplant (BMT) model, in which administration of anti-CD40 antibody early after BMT results in overproduction of interleukin-12 (IL-12) and interferon-\u03b3 (IFN-\u03b3), and lethal gut toxicity to examine the protective effect of the spin trap inhibitor, alpha phenyl-tert-butyl nitrone (PBN). Administration of PBN protected transplant recipients from mortality by significantly attenuating gut toxicity, but did not effect a reduction in the levels of proinflammatory cytokines (IL-12, IFN-\u03b3, tumor necrosis factor \u03b1 [TNF-\u03b1], or nitrate\/nitrite). Moreover, PBN did not compromise anti-CD40 antibody-mediated antitumor effects in a nontransplantation lymphoma model. Collectively, these data suggest that PBN administration may represent a novel approach for reduction of toxicity without compromise of antitumor effects resulting from administration of therapeutic antibodies in both transplantation and nontransplantation settings. (Blood. 2005;105:428-431)<\/jats:p>","DOI":"10.1182\/blood-2004-01-0371","type":"journal-article","created":{"date-parts":[[2004,8,27]],"date-time":"2004-08-27T00:14:41Z","timestamp":1093565681000},"page":"428-431","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration"],"prefix":"10.1182","volume":"105","author":[{"given":"Maria","family":"Gendelman","sequence":"first","affiliation":[{"name":"From the Bone Marrow Transplant Program and the Departments of Medicine, Pathology, Biostatistics, and Pediatric Surgery, Medical College of Wisconsin, Milwaukee, WI; the Department of Microbiology and Immunology, University of Nevada-Reno, Reno, NV; and the Department of Pediatrics, University of Minnesota, Minneapolis, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Halligan","sequence":"additional","affiliation":[{"name":"From the Bone Marrow Transplant Program and the Departments of Medicine, Pathology, Biostatistics, and Pediatric Surgery, Medical College of Wisconsin, Milwaukee, WI; the Department of Microbiology and Immunology, University of Nevada-Reno, Reno, NV; and the Department of Pediatrics, University of Minnesota, Minneapolis, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Komorowski","sequence":"additional","affiliation":[{"name":"From the Bone Marrow Transplant Program and the Departments of Medicine, Pathology, Biostatistics, and Pediatric Surgery, Medical College of Wisconsin, Milwaukee, WI; the Department of Microbiology and Immunology, University of Nevada-Reno, Reno, NV; and the Department of Pediatrics, University of Minnesota, Minneapolis, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Logan","sequence":"additional","affiliation":[{"name":"From the Bone Marrow Transplant Program and the Departments of Medicine, Pathology, Biostatistics, and Pediatric Surgery, Medical College of Wisconsin, Milwaukee, WI; the Department of Microbiology and Immunology, University of Nevada-Reno, Reno, NV; and the Department of Pediatrics, University of Minnesota, Minneapolis, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Murphy","sequence":"additional","affiliation":[{"name":"From the Bone Marrow Transplant Program and the Departments of Medicine, Pathology, Biostatistics, and Pediatric Surgery, Medical College of Wisconsin, Milwaukee, WI; the Department of Microbiology and Immunology, University of Nevada-Reno, Reno, NV; and the Department of Pediatrics, University of Minnesota, Minneapolis, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce R.","family":"Blazar","sequence":"additional","affiliation":[{"name":"From the Bone Marrow Transplant Program and the Departments of Medicine, Pathology, Biostatistics, and Pediatric Surgery, Medical College of Wisconsin, Milwaukee, WI; the Department of Microbiology and Immunology, University of Nevada-Reno, Reno, NV; and the Department of Pediatrics, University of Minnesota, Minneapolis, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Kirkwood A.","family":"Pritchard","sequence":"additional","affiliation":[{"name":"From the Bone Marrow Transplant Program and the Departments of Medicine, Pathology, Biostatistics, and Pediatric Surgery, Medical College of Wisconsin, Milwaukee, WI; the Department of Microbiology and Immunology, University of Nevada-Reno, Reno, NV; and the Department of Pediatrics, University of Minnesota, Minneapolis, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Drobyski","sequence":"additional","affiliation":[{"name":"From the Bone Marrow Transplant Program and the Departments of Medicine, Pathology, Biostatistics, and Pediatric Surgery, Medical College of Wisconsin, Milwaukee, WI; the Department of Microbiology and Immunology, University of Nevada-Reno, Reno, NV; and the Department of Pediatrics, University of Minnesota, Minneapolis, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021219160221900_REF1","doi-asserted-by":"crossref","unstructured":"Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med.1985;313: 1485-1492.","DOI":"10.1056\/NEJM198512053132327"},{"key":"2020021219160221900_REF2","doi-asserted-by":"crossref","unstructured":"Lotze MT, Matory YL, Rayner AA, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer.1986;58: 2764-2772.","DOI":"10.1002\/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z"},{"key":"2020021219160221900_REF3","doi-asserted-by":"crossref","unstructured":"Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH. Administration of interleukin-12 with pulse interleukin-2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst.1996;88: 38-43.","DOI":"10.1093\/jnci\/88.1.38"},{"key":"2020021219160221900_REF4","doi-asserted-by":"crossref","unstructured":"Coughlin CM, Salhany KE, Wysocka M, et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest.1998;101: 1441-1452.","DOI":"10.1172\/JCI1555"},{"key":"2020021219160221900_REF5","doi-asserted-by":"crossref","unstructured":"French RR, Chan HTC, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T cell response that eradicates lymphoma and bypasses T cell help. Nat Med.1999;5: 548-553.","DOI":"10.1038\/8426"},{"key":"2020021219160221900_REF6","doi-asserted-by":"crossref","unstructured":"Honeychurch J, Glennie MJ, Johnson PWM, Illidge TM. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T cell dependent immunity to B cell lymphoma. Blood.2003;102: 1449-1457.","DOI":"10.1182\/blood-2002-12-3717"},{"key":"2020021219160221900_REF7","doi-asserted-by":"crossref","unstructured":"Bilber JL, Jabbour S, Parihar R, et al. Administration of two macrophage-derived interferon-gamma-inducing factors (IL-12 and IL-15) induces a lethal systemic inflammatory response in mice that is dependent on natural killer cells but does not require interferon gamma. Cell Immunol.2002;216: 31-42.","DOI":"10.1016\/S0008-8749(02)00501-4"},{"key":"2020021219160221900_REF8","doi-asserted-by":"crossref","unstructured":"Okamoto M, Kato S, Oizumi K, et al. Interleukin 18 (IL-18) in synergy with IL-12 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood.2002;99: 1289-1298.","DOI":"10.1182\/blood.V99.4.1289"},{"key":"2020021219160221900_REF9","doi-asserted-by":"crossref","unstructured":"Carson WE, Yu H, Dierksheide J, et al. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J Immunol.1999;162: 4943-4951.","DOI":"10.4049\/jimmunol.162.8.4943"},{"key":"2020021219160221900_REF10","doi-asserted-by":"crossref","unstructured":"Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft versus host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood.1997;90: 3204-3213.","DOI":"10.1182\/blood.V90.8.3204"},{"key":"2020021219160221900_REF11","unstructured":"Janzen EG, Haire DL. Two decades of spin trapping. In: Tanner DD, ed. Advances in Free Radical Chemistry. Greenwich, CT: JAI Press; 1990: 253-295."},{"key":"2020021219160221900_REF12","doi-asserted-by":"crossref","unstructured":"Naito Y, Takagi T, Ishikawa T, et al. \u03b1-Phenyl-N-tert-butyl nitrone provides protection from dextran sulfate sodium-induced colitis in mice. Redox Signal.2002;4: 195-206.","DOI":"10.1089\/152308602753625951"},{"key":"2020021219160221900_REF13","doi-asserted-by":"crossref","unstructured":"Ho E, Chen G, Bray TM. Alpha-phenyl-tert-butylnitrone (PBN) inhibits NFkB activation offering protection against chemically induced diabetes. Free Rad Biol Med.2000;28: 604-614.","DOI":"10.1016\/S0891-5849(99)00271-3"},{"key":"2020021219160221900_REF14","doi-asserted-by":"crossref","unstructured":"Kotake Y, Sang H, Wallis GL, Stewart CA. Phenyl N-tert-butyl nitrone provides protection from endotoxin shock through amplified production of the anti-inflammatory cytokine interleukin-10. Arch Biochem Biophys.1999;371: 129-131.","DOI":"10.1006\/abbi.1999.1417"},{"key":"2020021219160221900_REF15","doi-asserted-by":"crossref","unstructured":"Hixon JA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ. Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant.2001;7: 136-143.","DOI":"10.1053\/bbmt.2001.v7.pm11302547"},{"key":"2020021219160221900_REF16","doi-asserted-by":"crossref","unstructured":"Hixon JA, Anver MR, Blazar BR, Panoskaltsis-Mortari A, Wiltrout RH, Murphy WJ. Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces lethal toxicity affecting the gut. Biol Blood Marrow Transplant.2002;8: 316-325.","DOI":"10.1016\/S1083-8791(02)50029-X"},{"key":"2020021219160221900_REF17","doi-asserted-by":"crossref","unstructured":"Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol.2002;168: 2720-2728.","DOI":"10.4049\/jimmunol.168.6.2720"},{"key":"2020021219160221900_REF18","doi-asserted-by":"crossref","unstructured":"Miyajima T, Kotake Y. Optimal time and dosage of phenyl N-tert-butyl nitrone (PBN) for the inhibition of nitric oxide synthase induction in mice. Free Rad Biol Med.1997;22: 463-470.","DOI":"10.1016\/S0891-5849(96)00391-7"},{"key":"2020021219160221900_REF19","doi-asserted-by":"crossref","unstructured":"Sang H, Wallis GL, Stewart CA, Kotake Y. Expression of cytokines and activation of transcription factors in lipopolysaccharide-administered rats and their inhibition by phenyl N-tert-butylnitrone (PBN). Arch Biochem Biophysic.1999;363: 341-348.","DOI":"10.1006\/abbi.1998.1086"},{"key":"2020021219160221900_REF20","doi-asserted-by":"crossref","unstructured":"Tabatabaie T, Graham KL, Vasquez AM, Floyd RA, Kotake Y. Inhibition of the cytokine-mediated inducible nitric oxide synthase expression in rat insulinoma cells by phenyl N-tert-butyl nitrone. Nitric Oxide.2000;4: 157-167.","DOI":"10.1006\/niox.2000.0281"},{"key":"2020021219160221900_REF21","doi-asserted-by":"crossref","unstructured":"Kotake Y, Moore DR, Vasquez-Walden A, Tabatabaie T, Sang H. Antioxidant amplifies antibiotic protection in the cecal ligation and puncture model of microbial sepsis through interleukin-10 production. Shock.2003;19: 252-256.","DOI":"10.1097\/00024382-200303000-00009"},{"key":"2020021219160221900_REF22","unstructured":"Lee JH, Park J. Protective role of \u03b1-phenyl-N-tbutylnitrone against ionizing radiation in U937 cells and mice. Cancer Res.2003;63: 6885-6893."},{"key":"2020021219160221900_REF23","doi-asserted-by":"crossref","unstructured":"Turner JG, Rakhmilevich AL, Burdelya L, et al. Anti-CD40 antibody induces antitumor and anti-metastatic effects: the role of NK cells. J Immunol.2001;166: 89-94.","DOI":"10.4049\/jimmunol.166.1.89"},{"key":"2020021219160221900_REF24","doi-asserted-by":"crossref","unstructured":"Murphy WJ, Hixon J, Back T, et al. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8 cell responses. J Immunol.2003;170: 2727-2733.","DOI":"10.4049\/jimmunol.170.5.2727"},{"key":"2020021219160221900_REF25","unstructured":"Klausner JM, Paterson IS, Goldman G, et al. Interleukin-2-induced lung injury is mediated by oxygen free radicals. Surgery.1991;109: 169-175."},{"key":"2020021219160221900_REF26","doi-asserted-by":"crossref","unstructured":"Samlowski WE, Petersen R, Cuzzocrea S, et al. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med.2003;9: 750-755.","DOI":"10.1038\/nm874"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/1\/428\/1705153\/zh800105000428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/1\/428\/1705153\/zh800105000428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T07:16:23Z","timestamp":1682752583000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/1\/428\/20019\/Alpha-phenyltertbutyl-nitrone-PBN-protects"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-01-0371","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}